A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib

European Journal of Cancer

Volumn 45, Issue 8, 2009, Pages 1518-1526

  Donovan, Michael J ^a   Kotsianti, Angeliki ^a   Bayer Zubek, Valentina ^a   Verbel, David ^a   Teverovskiy, Mikhail ^a   Cordon Cardo, Carlos ^a,b   Costa, Jose ^a,c   Greco, F Anthony ^d   Hainsworth, John D ^d   Parums, Dinah V ^e  

^a Aureon Laboratories Inc   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SARAH CANNON RESEARCH INSTITUTE   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Biological tumour markers; Clinical pathology; Epidermal growth factor receptor; Gefitinib; Non small cell lung carcinoma; Statistical models; Survival analysis

Indexed keywords

CASPASE 3; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN TYROSINE KINASE; VASCULOTROPIN RECEPTOR 2;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOMETRY; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MODEL; MORPHOMETRICS; MULTIVARIATE ANALYSIS; MUTATION; OVERALL SURVIVAL; PATHOLOGY; PERFORMANCE; PREDICTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SAMPLE; SUPPORT VECTOR MACHINE; VALIDATION STUDY;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CYCLIN D1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 65249147752     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.02.004     Document Type: Article

References (30)

1. Giaccone G., Herbst R.S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
2. Herbst R.S., Giaccone G., Schiller J.H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 (2004) 785-794
3. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
4. Dudek A.Z., Kmak K.L., Koopmeiners J., and Keshtgarpour M. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer. Lung Cancer 51 (2006) 89-96
5. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med 350 (2004) 2129-2139
6. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
7. Cappuzzo F., Hirsch F.R., Rossi E., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
8. Sequist L.V., Martins R.G., Spigel D., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26 (2008) 2442-2449
9. Kim E.S., Hirsh V., and Mok T. Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST): a randomized phase III trial. Lancet 372 (2008) 1809-1818
10. Cordon-Cardo C., Kotsianti A., Verbel D.A., et al. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest 117 (2007) 1876-1883
11. Muss H.B., Bunn J.Y., Crocker A., et al. Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen. Breast J 13 (2007) 337-345
12. Donovan M.J., Hamann S., Clayton M., et al. Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol 26 (2008) 3923-3929
13. Saidi O., Cordon-Cardo C., and Costa J. Technology insight: will systems pathology replace the pathologist?. Nat Clin Pract Urol 4 (2007) 39-45
14. Yan L., Verbel D., and Saidi O. Predicting prostate cancer recurrence via maximizing the concordance index. In: Kohavi R., Gehrke J., DuMouchel W., and Ghosh J. (Eds). Proceedings of the tenth ACM SIGKDD international conference on knowledge discovery and data mining (2004), ACM Press 479-485
15. Zubek V., Verbel D., and Saidi O. Censored time trees for predicting time to PSA recurrence. Proceedings of the fourth international conference on machine learning and applications (ICMLA 2005) (2005), IEEE Computer Society, Washington, DC 221-226
16. Mazumdar M., and Glassman J.R. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med 19 (2000) 113-132
17. Stephenson A.J., Scardino P.T., Eastham J.A., et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98 (2006) 715-717
18. Jeon Y.K., Sung S.W., Chung J.H., et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 54 (2006) 387-398
19. Bell D.W., Gore I., Okimoto R.A., et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37 (2005) 1315-1316
20. Hainsworth J.D., Mainwaring M.G., Thomas M., et al. Gefitinib in the treatment of advanced, refractory non-small-cell lung cancer: results in 124 patients. Clin Lung Cancer 4 (2003) 347-355
21. Su W.P., Yang C.H., Yu C.J., Shih J.Y., Hsu C., and Yang P.C. Gefitinib treatment for non-small cell lung cancer - a study including patients with poor performance status. J Formos Med Assoc 104 (2005) 557-562
22. Erman M., Grunenwald D., Penault-Llorca F., et al. Epidermal growth factor receptor, HER-2/neu and related pathways in lung adenocarcinomas with bronchioloalveolar features. Lung Cancer 47 (2005) 315-323
23. Bailey L., Janas M., Schmidt K., et al. Evaluation of epidermal growth factor receptor (EGFR) as a predictive marker in patients with non-small-cell lung cancer (NSCLC) receiving first-line gefitinib combined with platinum-based chemotherapy. J Clin Oncol 22 (2004) 7013 [abstr.]
24. Bailey L., Kris M., Wolf M., et al. Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gifitinib (Iressa, ZD 1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Proc Am Assoc Cancer Res 44 (2003) 1362 abstr.
25. Jin M., Inoue S., Umemura T., et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 34 (2001) 207-218
26. Keum J.S., Kong G., Yang S.C., et al. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. Brit J Cancer 81 (1999) 127-132
27. Koomagi R., and Volm M. Relationship between the expression of caspase-3 and the clinical outcome of patients with non-small cell lung cancer. Anticancer Res 20 (2000) 493-496
28. Takata T., Tanaka F., Yamada T., et al. Clinical significance of caspase-3 expression in pathologic-stage I, nonsmall-cell lung cancer. Int J Cancer 96 Suppl. (2001) 54-60
29. Seto T., Higashiyama M., Funai H., et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage 1 non-small-cell lung cancer. Lung Cancer 53 (2006) 91-96
30. Mineo T.C., Ambrogi V., Baldi A., et al. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol 57 (2004) 591-597